Krsnaa Diagnostics to launch 600 new diagnostics centres across India

India Pharma Outlook Team | Thursday, 29 September 2022

 India Pharma Outlook Team

Krsnaa Diagnostics, a leading player in the diagnostics space, announced its plans to launch 600 diagnostics centres across India. The firm will strengthen its footprint across Maharashtra, Himachal Pradesh, Punjab, West Bengal, and Rajasthan, with the spread across metros, tier 2 and tier 3 cities. The centres will be equipped to offer specialized services in precision medicine, genetics, genomics, and molecular diagnostics, along with the routine investigations of biochemistry and serology, which are commonly used in routine diagnostics tests. The centres will offer dedicated services for women’s health (hormones/ PCOD), diabetes monitoring, cardiac health, and cancer care. Krsnaa Diagnostics is the largest service provider of radiology and diagnostics services under a single roof in India.

Currently, the company is present in 16 states and 2 Union Territories of India with 2,000 plus locations. Sharing the company’s vision, Pallavi Jain, managing director of Krsnaa Diagnostics said, “Krsnaa Diagnostics has always been at the forefront when it comes to serving the healthcare needs of our society. Considering the rising demand for diagnostics services and to cater to the remotest parts of the country, we have decided to enter deep markets through a franchise model. With this expansion, we wish to take the high-end infrastructure and best-in-class diagnostics services to more people across the country.

” Commenting on the initiative, chief operating officer, Ravinder Sethi said, “Currently, we operate most of our centres through hospitals. This initiative is set to bolster and accelerate our footprint in India and improve healthcare access for patients. With this launch, we are getting closer to the patients to ensure we are present in places where there is unmet needs of healthcare delivery. Krsnaa Diagnostics is one of the largest diagnostics player offering disruptive competitive prices to its customers.”

© 2025 India Pharma Outlook. All Rights Reserved.